Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- (-) Value Assessment
- (-) Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Resource Type
Audience
Display Only
Showing 65 Results
QALY Remains a Challenge, Societal Perspective Presents an Opportunity With ICER’s 2020 Value Assessment Framework
NPC evaluates the extent to which ICER's 2020-2023 value assessment framework addresses needed changes.
Women Matter in Value Assessments
Sarah Wells Kocsis explains why the Society for Women's Health Research is calling on the Institute for Clinical and Economic Review to ensure its value frameworks and assessments “reflect factors…
Value Assessments Should Encompass More Than Just Medicines
NPC submitted comments to the Institute for Clinical and Economic Review in response to its request for non-drug assessment topics, noting that value assessments should encompass more than just…
Considering the Needs of Older Patients in Value Assessments
When we consider health care value, how can we assess the challenges faced by older patients with multiple diseases and their caregivers when making unique choices about their treatment options? It’s…
Concerns Raised About ICER’s Adapted Value Assessment Methods for High-Impact ‘Single and Short-term Therapies’
NPC outlines concerns with ICER's final adaptations to its value assessment framework for use when reviewing curative therapies.
NPC Analysis Compares, Contrasts 7 U.S. Value Assessment Frameworks
The National Pharmaceutical Council (NPC) today released an analysis of seven U.S. value assessment frameworks, comparing and contrasting the strengths and limitations associated with each framework…
Six Ways ICER Changes Benefit the Payer, Not the Patient
NPC Executive Vice President and Chief Science Officer Robert W. Dubois, MD, PhD, examines what more is needed to balance stakeholder needs and ensure that patients are an integral part of the value…
Latest ICER Report Relies on Incomplete Evidence, Inadequate Analyses
It’s troubling to see a new report from the Institute for Clinical and Economic Review (ICER) that used incomplete evidence and inadequate analyses.
More Than Just One Number: Assessing The Value of Innovative Treatments
In a commentary for Specialty Pharmacy Times, National Pharmaceutical Council (NPC) President and CEO Dan Leonard takes a closer look at what changes are needed to ensure that value assessments can…
NPC Weighs in on ICER’s Approaches to Valuing Cures
Within the last few years, we’ve seen the development of treatments to cure specific types of blindness, cancers and hepatitis C. In coming years, we’re anticipating the Food and Drug Administration…
Are Value Assessment Frameworks Ready for Prime Time?
An analysis from NPC, published in Value in Health, examined efforts from three organizations actively conducting value assessments.
Value Assessments: Incorporating Patient Benefits and Perspectives in ICER Reviews of Allergy and Asthma Treatments
Tonya Winders, CEO and President, Allergy & Asthma Network (AAN), discusses her involvement in the peanut allergy value assessment process and shares her experiences in working with her members…
NPC in AJMC: Why We Need Multiple Measures of Cost-Effectiveness in the US
In an editorial for The American Journal of Managed Care, NPC Chief Science Officer and Executive Vice President Dr. Robert Dubois explores the pitfalls of assigning only one organization the…
Rethinking Our Approach to Value Assessment to Ensure the Patient Voice is Heard
According to a panel at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Summit 2018 and summarized this week in Value in Health, even though value assessment frameworks…
NPC Outlines Ways to Make ICER’s Value Assessment Framework More Patient-Centered
NPC submitted comments to the Institute for Clinical and Economic Review (ICER) on ways to improve its value assessment framework and ensure that patient concerns are better addressed in treatment…
NAMI Highlights Concerns With ICER's Review of TRD
Seven percent of adults in the U.S. — an estimated 16 million people — experienced at least one major depressive episode in 2016 alone. Depression can be difficult to treat effectively because of…
Public Input Is a Key Way to Improve Value Assessment Process
This week, the Institute for Clinical and Economic Review (ICER) has announced that it is planning to revise its value assessment framework process. In a perfect world, every framework developer…
Access to Care: Development of a Medication Access Framework for Quality Measurement
A new framework, developed by the Pharmacy Quality Alliance (PQA) and supported by the National Pharmaceutical Council (NPC), identified seven main areas patients encounter while seeking access to…
In Value Assessment, Additional Voices Bring Much-needed Alternative Perspectives
In an interview published in the Journal of Clinical Pathways, the Innovation and Value Initiative details why value assessment is a critical field in the future of health care, highlights patient…
Personalized Medicine in a World of Value Frameworks
In a commentary published in the Journal of Clinical Pathways, NPC's Dr. Robert W. Dubois explores how to improve value frameworks’ approach to personalized medicine.